Bharat Parenterals gets DCGI approval for favipiravir oral suspension

Bharat Parenterals’ favipiravir oral suspension has recently received approval from the Drugs Controller General of India (DCGI) for treatment of COVID-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir is an antiviral drug approved in Japan in 2014 for the treatment of new or re-emerging influenza virus infections.